GlassScriptPhysician profile
Lance Curtis Robinson
NPI 1437686474
$1,236.11
in general payments reported to CMS, 2019-2025
26 companies · $219 in 2025
The $219 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $131 · 2021: $224 · 2022: $346 · 2023: $164 · 2024: $152 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $204.65 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Novo Nordisk INC | $155.28 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $130.01 | 2021 | |
| Abbvie INC. | $112.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.33 | 2022-2025 | Jardiance |
| Biogen, INC. | $55.42 | 2025 | Zurzuvae |
| Dexcom, INC. | $44.65 | 2022-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $42.36 | 2021-2022 | |
| Axsome Therapeutics, INC. | $40.35 | 2023-2025 | Auvelity |
| Glaxosmithkline, LLC. | $36.56 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $36.47 | 2021-2022 | |
| Pfizer INC. | $32.50 | 2024-2025 | |
| Allergan, INC. | $24.48 | 2020 | |
| Merck Sharp & Dohme LLC | $24.36 | 2025 | Proquad, Capvaxive, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $22.48 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.38 | 2024 | Caplyta |
| Abbott Laboratories | $22.05 | 2024 | Eterna |
| Novartis Pharmaceuticals Corporation | $18.48 | 2024 | |
| Exact Sciences Corporation | $17.86 | 2024 | Cologuard Collection Kit |
| Genzyme Corporation | $17.46 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $17.30 | 2025 | Exparel |
| Organon LLC | $16.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.87 | 2022 | |
| Astellas Pharma US INC | $15.40 | 2023 | Veozah |
| Astrazeneca Pharmaceuticals LP | $14.47 | 2022 | |
| Edwards Lifesciences Corporation | $13.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.